Loading stock data…
Arvinas, Inc. (ARVN)
$9.08-0.31 (-3.30%)
After Hours$9.08+0.00 (+0.00%)· Last close Sep 8
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Arvinas, Inc. in the Healthcare sector is trading at $9.08 with a market capitalization of $606M. Wall Street consensus targets $13.93 (14 analysts), implying a +53.4% move over the next 12 months. The stock is currently 37% below its 52-week high of $14.51, remaining 13.7% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +53.4% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $15.60M↑ | $9.50M↓ | $41.90M↑ | $22.40M↓ | $188.80M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$63.80M↑ | -$74.60M↓ | -$43.80M↑ | -$71.50M↓ | $71.40M |
| Net Income | -$57.60M↑ | -$67.40M↓ | -$35.10M↑ | -$61.20M↓ | $82.90M |
Peer Comparison
JNJUNHPFE
Fundamentals
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degrad...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$605.85M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
36.12
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.76
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
1.65%
Volume
Today's trading volume
570,209
Recent News
Can KT-621 Mark a Turning Point for Kymera Therapeutics?
KYMR advances KT-621 in atopic dermatitis and asthma, with earlier-than-expected AD data and potential phase III plans by mid-2027.
Arvinas (ARVN) Q2 2026 Earnings Call Transcript
VEPPANU's FDA approval and $50 million Pfizer milestone fuel record net income.
Arcus Biosciences' Casdatifan Therapy Could be Launched in 2028, Morgan Stanley Says
Arcus Biosciences (RCUS) Casdatifan therapy for renal cell carcinoma could be launched in 2028 and p
Arvinas (ARVN) Upgraded to Strong Buy: Here's What You Should Know
Arvinas (ARVN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Arvinas, Inc. Q2 2026 Earnings Call Summary
Moby summary of Arvinas, Inc.'s Q2 2026 earnings call